SPOTLIGHT: ReNeuron looks to resolve FDA issues

ReNeuron is hoping that a meeting Feb. 14 with FDA officials will resolve the agency's concerns over its ReN001 stem cell therapy, which prompted the agency to put a clinical hold on the therapy. Release

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.